Examples of Analytical Method Implementation

Recommendation
18-20 November 2025
Heidelberg, Germany
GMP and FDA Compliance in Pharmaceutical Development and IMP Manufacturing
Following the recently introduced new Ph. Eur. chapter 5.26 Implementation of pharmacopoeial procedures (Ph. Eur. 11.0), the EDQM published some examples. The intention is to provide users with practical guidance on how critical factors potentially affecting the Analytical Procedure Performance Characteristics (APPCs) can be identified. However, it is emphasized, that the pre-requisite for the implementation of any analytical procedure is a suitable quality system, which ensures that the requirements set for personnel, premises, and equipment are fulfilled.
Examples for Critical Factor Assessment
The following six examples are provided for the assessment of critical factors associated with the analytical procedure under actual conditions:
- Pharmaceutical ingredient (Mannitol) / Identification by infrared absorption spectrophotometry
- Drug product (Deferiprone tablets) / Related substances test by LC-UV
- Active substance (Benzylpenicillin potassium) / Assay by LC-UV
- Infliximab concentrated solution / Cell-based assay procedures
- Drug Product (Deferiprone oral solution) / Microbial enumeration test
- Active substance (Deferiprone) / Sulfated ash
More information is available in the Examples of implementation of pharmacopoeial procedures according to Chapter 5.26 "Implementation of pharmacopoeial procedures” published in Pharmeuropa Online under Technical Information.
Related GMP News
17.09.2025USP-NF Stimuli Article on Apex Vessels used in Dissolution Testing: Corrected Version Published
17.09.2025Who is allowed to perform Sampling?
27.08.2025FDA Warning Letter: Missing Identity Tests, Unverified CoAs, and Inadequate DEG/EG Controls
20.08.2025USP Responds to Comments on Chapter <202> HPTLC Identification of Fixed Oils
13.08.2025USP publishes Comments rereived on Chapter <317>
13.08.2025FDA Issues Warning Letter to Contract Testing Laboratory for Inadequate OOS Investigations